New drug shown to slow Alzheimer’s progress
New York | An experimental Alzheimer’s drug made by US pharmaceuticals group Eli Lilly slowed cognitive decline in early-stage patients, data confirmed on Monday (Tuesday AEST), putting it on course to be the second treatment approved within months that alters the course of the disease.
Eli Lilly said it applied for full US approval of its Alzheimer’s disease drug that is expected to compete with Eisai’s Leqembi after the drugmaker revealed details of a final-stage trial at a conference in Amsterdam.
Bloomberg
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In North America
Fetching latest articles